STOCK TITAN

Foghorn Therapeutics (FHTX) Financials

FHTX NASDAQ
Trailing 12 months to September 30, 2026
Revenue $112.1M +357.3% YoY
Net Income $9.4M n/m YoY
EPS (Diluted) $0.07 n/m YoY
Free Cash Flow -$83.7M n/m YoY
Market Cap $103.1M as of Nov 20, 2026
Price / Sales 0.9x on $112.1M revenue, trailing 12 months to September 30, 2026
Price / Earnings 10.9x on $9.4M net income, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FHTX SEC filings page.

Foghorn Therapeutics Inc. (FHTX) reported $112.1M in revenue over the twelve months to Sep 30, 2026, up 357.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FHTX FY2025

Foghorn remains a development-stage business: revenue recovered, but research spending still exceeds sales and cash generation remains negative.

The revenue recovery to $30.9M occurred while R&D remained $85.5M, so development spending is still far above the commercial base. R&D intensity fell to 276.5% from 418.2%, indicating the reported operating improvement came partly from spending restraint rather than a self-funding model.

The latest operating loss was $86.4M and operating cash flow was -$86.1M; their close alignment means reported losses are accompanied by a similar cash requirement, not merely non-cash accounting pressure. That earnings-to-cash relationship matters more here than capital spending, which was only $50K.

Liabilities of $306.6M exceeded assets of $198.1M, producing negative equity and showing that the balance sheet is financed with obligations rather than shareholder capital. The current ratio was 2.7x, while reported liquidity equaled 11.3 months of latest annual operating outflow; short-term coverage is narrowing alongside the asset base.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 50 / 100
Financial Health Score 50/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Foghorn Therapeutics Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
34

Foghorn Therapeutics Inc. held $80.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $86.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Foghorn Therapeutics Inc. scores 34/100 among other emerging companies.

Dilution
44

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Foghorn Therapeutics Inc. scores 44/100 on it among other emerging companies.

R&D Intensity
91

Foghorn Therapeutics Inc. spent $85.5M on research and development in fiscal year 2025, which was 72.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Foghorn Therapeutics Inc. scores 91/100 among other emerging companies.

Revenue Progress
36

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Foghorn Therapeutics Inc. scores 36/100 on it among other emerging companies.

Burn Trend
63

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Foghorn Therapeutics Inc. scores 63/100 on it among other emerging companies.

Balance Sheet
32

Foghorn Therapeutics Inc.'s cash, cash equivalents and investments came to $80.9M at the end of fiscal year 2025, against $306.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Foghorn Therapeutics Inc. scores 32/100 among other emerging companies.

Altman Z-Score Distress
-4.92

Foghorn Therapeutics Inc. scores -4.92, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $632.5M against total assets of $198.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
1/7

Foghorn Therapeutics Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Foghorn Therapeutics Inc. reported a net loss of $74.3M while operations used $86.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$83.5M
YoY+924.7%
QoQ+419.8%
5Y CAGR+359.0%

Foghorn Therapeutics Inc. generated $83.5M in revenue in Q3 2026. This represents an increase of 924.7% from the same quarter a year earlier. Against the prior quarter it is up 419.8%.

EBITDA
$56.8M
YoYn/m
QoQn/m
5Y CAGRn/m

Foghorn Therapeutics Inc.'s EBITDA was $56.8M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
$58.1M
YoYn/m
QoQn/m
5Y CAGRn/m

Foghorn Therapeutics Inc. reported $58.1M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
$0.80
YoYn/m
QoQn/m
5Y CAGRn/m

Foghorn Therapeutics Inc. earned $0.80 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$18.3M
YoYn/m
QoQn/m
5Y CAGRn/m

Foghorn Therapeutics Inc. recorded an outflow of $18.3M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$80.3M
YoY-10.1%
QoQ+18.0%
5Y CAGR+6.8%

Foghorn Therapeutics Inc. held $80.3M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
60M
YoY+6.0%
QoQ+1.0%
5Y CAGR+10.1%

Foghorn Therapeutics Inc. had 60M shares outstanding in Q3 2026. This represents an increase of 6.0% from the same quarter a year earlier. Against the prior quarter it is up 1.0%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Operating Margin
67.8%
QoQ+122.6pp

Foghorn Therapeutics Inc.'s operating margin was 67.8% in Q3 2026, reflecting core business profitability. Against the prior quarter it is up 122.6 percentage points. No change is given against Q3 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin
69.6%
QoQ+114.3pp

Foghorn Therapeutics Inc.'s net profit margin was 69.6% in Q3 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 114.3 percentage points. No change is given against Q3 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Gross Margin

Not reported for Q3 2026.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$18.8M
YoY-5.8%
QoQ+1.7%
5Y CAGR-1.7%

Foghorn Therapeutics Inc. invested $18.8M in research and development in Q3 2026. This represents a decrease of 5.8% from the same quarter a year earlier. Against the prior quarter it is up 1.7%.

Capital Expenditures
$7K
YoYn/m
QoQ-86.0%
5Y CAGR-50.3%

Foghorn Therapeutics Inc. invested $7K in capex in Q3 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 86.0%.

Share Buybacks

Not reported for Q3 2026.

FHTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FHTX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$83.5M+924.7%$16.1M+112.7%$3.3M-45.1%$9.2M+223.8%$8.2M+4.4%$7.6M+9.7%$6.0M+17.9%$2.9M-50.5%
R&D Expenses$18.8M-5.8%$18.5M-15.0%$18.3M-15.6%$22.0M+7.5%$20.0M-19.0%$21.8M-8.4%$21.6M-15.3%$20.5M-15.3%
SG&A Expenses$5.8M-12.9%$6.4M-7.4%$6.6M-9.1%$6.8M+7.0%$6.7M-4.6%$6.9M-6.3%$7.2M-6.1%$6.4M-9.5%
Operating Income$56.6Mn/m-$8.8Mn/m-$21.6Mn/m-$23.9Mn/m-$18.5Mn/m-$21.1Mn/m-$22.9Mn/m-$24.0Mn/m
EBITDA$56.8Mn/m-$8.6Mn/m-$21.3Mn/m-$23.1Mn/m-$17.6Mn/m-$20.2Mn/m-$22.1Mn/m-$23.2Mn/m
Income TaxN/AN/AN/AN/AN/AN/AN/A$0-100.0%
Net Income$58.1Mn/m-$7.2Mn/m-$19.9Mn/m-$21.7Mn/m-$15.8Mn/m-$17.9Mn/m-$18.8Mn/m-$19.5Mn/m
EPS (Basic)$0.81n/m-$0.10n/m-$0.29n/m-$0.34n/m-$0.25n/m-$0.28n/m-$0.30n/m-$0.30
EPS (Diluted)$0.80n/m-$0.10n/m-$0.29n/m-$0.34n/m-$0.25n/m-$0.28n/m-$0.30n/m-$0.30
Diluted Shares (Avg)73M+15.2%71M+12.1%70M+10.6%N/A63M+0.7%63M+22.1%63M+48.1%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

FHTX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FHTX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$191.0M-6.8%$203.4M-10.1%$222.2M-14.1%$198.1M-30.2%$205.0M-33.5%$226.2M-31.1%$258.7M+1.4%$284.0M-0.7%
Current Assets$158.3M-14.0%$170.0M-16.6%$188.1M-16.6%$163.2M-34.6%$184.1M-32.1%$203.8M-29.6%$225.4M+6.6%$249.6M+3.9%
Cash & Equivalents$80.3M-10.1%$68.1M-6.2%$87.7M+43.6%$80.9M+45.8%$89.3M+54.9%$72.6M-47.8%$61.0M-23.0%$55.5M-31.0%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$205.0M-30.4%$284.4M-6.1%$298.6M-6.8%$306.6M-7.0%$294.6M-12.5%$302.9M-11.7%$320.3M-9.1%$329.5M-9.3%
Current Liabilities$37.3M-56.1%$50.6M-35.0%$64.4M-9.7%$59.7M-10.8%$85.1M+49.7%$77.8M+52.9%$71.3M+37.0%$67.0M+14.6%
Non-Current Liabilities$167.7M-20.0%$233.9M+3.9%$234.2M-6.0%$246.9M-6.0%$209.5M-25.1%$225.1M-22.9%$249.0M-17.1%$262.5M-13.8%
Total Equity-$14.1Mn/m-$81.0Mn/m-$76.4Mn/m-$108.5Mn/m-$89.7Mn/m-$76.7Mn/m-$61.7Mn/m-$45.5Mn/m
Retained Earnings-$601.4Mn/m-$659.5Mn/m-$652.3Mn/m-$632.5Mn/m-$610.8Mn/m-$595.0Mn/m-$577.0Mn/m-$558.2Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

FHTX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FHTX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$18.2Mn/m-$17.8Mn/m-$25.3Mn/m-$22.3Mn/m-$18.9Mn/m-$21.0Mn/m-$24.0Mn/m-$24.5Mn/m
Depreciation & Amortization$200K-77.8%$200K-77.8%$238K-71.2%$802K+5.4%$900K+28.6%$900K+12.5%$827K-1.0%$761K-10.7%
Stock-Based Compensation$2.5M-7.8%$2.5M-6.7%$2.4M-11.5%N/A$2.7M-9.4%$2.7M-13.7%$2.7M-16.5%N/A
Capital Expenditures$7Kn/m$50K+127.3%$0-100.0%$0-100.0%$0-100.0%$22K+29.4%$28K-72.3%$479K+1194.6%
Free Cash Flow-$18.3Mn/m-$17.9Mn/m-$25.3Mn/m-$22.3Mn/m-$18.9Mn/m-$21.0Mn/m-$24.0Mn/m-$25.0Mn/m
Investing Cash Flow$24.2M-32.0%-$3.0M-108.8%-$17.7M-160.3%$13.2M-40.6%$35.6Mn/m$33.8Mn/m$29.4M+8.5%$22.3M-40.4%
Financing Cash Flow$6.3M+12708.2%-$22K-108.7%$49.8M+35707.2%$581K+14425.0%$49K-95.3%$254K-99.8%$139K-88.1%$4K-97.8%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

FHTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FHTX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin67.8%-54.8%-660.3%-258.2%-226.9%-279.2%-385.0%-840.5%
Net Margin69.6%-44.7%-608.4%-234.3%-194.4%-237.3%-316.4%-682.9%
Return on Assets30.4%+38.2pp-3.5%+4.4pp-8.9%-1.7pp-10.9%-4.1pp-7.7%-1.5pp-7.9%-0.9pp-7.3%+2.5pp-6.9%+1.6pp
Current Ratio4.24+2.1x3.36+0.7x2.92-0.2x2.73-1.0x2.16-2.6x2.62-3.1x3.16-0.9x3.73-0.4x
Asset Turnover0.44+0.4x0.080.0x0.010.0x0.050.0x0.040.0x0.030.0x0.020.0x0.010.0x
FCF Margin-21.9%-111.3%-773.4%-240.8%-231.3%-278.2%-403.2%-875.3%

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$108.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Foghorn Therapeutics Inc. FHTX FY2025 $30.9M -$74.3M N/A $103.1M 50/100
Compass Therapeutics, Inc. CMPX FY2025 $0 -$66.5M N/A $123.9M —
Cue Biopharma, Inc. CUE FY2025 $27.5M -$26.6M -96.9% $34.7M 64/100
Cellectis S.A. CLLS FY2025 $72.9M -$67.6M -92.7% $92.8M 78/100
OnKure Therapeutics, Inc. OKUR FY2025 N/A -$59.5M N/A $111.2M —
Armata Pharmaceuticals, Inc. ARMP FY2025 N/A -$173.8M N/A $112.7M —

Frequently Asked Questions

Foghorn Therapeutics Inc. (FHTX) reported $30.9M in total revenue for fiscal year 2025. This represents a 36.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Foghorn Therapeutics Inc. (FHTX) revenue grew by 36.8% year-over-year, from $22.6M to $30.9M in fiscal year 2025.

Yes, Foghorn Therapeutics Inc. (FHTX) reported a net income of $9.4M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $74.3M.

Foghorn Therapeutics Inc. (FHTX) reported diluted earnings per share of -$1.18 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Foghorn Therapeutics Inc. (FHTX) had EBITDA of -$83.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Foghorn Therapeutics Inc. (FHTX) recorded an outflow of $86.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Foghorn Therapeutics Inc. (FHTX) recorded an outflow of $86.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Foghorn Therapeutics Inc. (FHTX) had $198.1M in total assets as of fiscal year 2025, including both current and long-term assets.

Foghorn Therapeutics Inc. (FHTX) invested $50K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Foghorn Therapeutics Inc. (FHTX) invested $85.5M in research and development during fiscal year 2025.

Foghorn Therapeutics Inc. (FHTX) had 59M shares outstanding as of fiscal year 2025.

Foghorn Therapeutics Inc. (FHTX) had a current ratio of 2.73 as of fiscal year 2025, which is generally considered healthy.

Foghorn Therapeutics Inc. (FHTX) had a return on assets of -37.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Foghorn Therapeutics Inc. (FHTX) trades at 10.9x earnings, its market capitalization divided by $9.4M net income, trailing 12 months to September 30, 2026. The market capitalization is $103.1M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Foghorn Therapeutics Inc. (FHTX) trades at 0.9x sales, its market capitalization divided by $112.1M revenue, trailing 12 months to September 30, 2026. The market capitalization is $103.1M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Foghorn Therapeutics Inc. (FHTX) held $80.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $86.1M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Foghorn Therapeutics Inc. (FHTX) has negative shareholder equity of -$108.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Foghorn Therapeutics Inc. (FHTX) has an Altman Z-Score of -4.92, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Foghorn Therapeutics Inc. (FHTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Foghorn Therapeutics Inc. (FHTX) reported a net loss of $74.3M while operations used $86.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Foghorn Therapeutics Inc. (FHTX) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top